GlassScriptPhysician profile
Barbara I Cerame
NPI 1316918832
$4,898.88
in general payments reported to CMS, 2019-2025
23 companies · $237 in 2025
The $237 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $112 · 2021: $107 · 2022: $131 · 2023: $3,944 · 2024: $203 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,060 · Food and Beverage: $851 · Travel and Lodging: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,060.00 |
| Food and Beverage | $850.53 |
| Travel and Lodging | $472.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,801.39 | 2020-2025 | |
| Ascendis Pharma Endocrinology INC | $187.03 | 2022-2024 | |
| Sanofi-Aventis U.S. LLC | $145.34 | 2023-2025 | |
| Insulet Corporation | $105.53 | 2019-2025 | Omnipod |
| Novo Nordisk INC | $91.05 | 2019-2025 | Sogroya |
| Dexcom, INC. | $68.86 | 2021-2025 | Dexcom G6 Transmitter |
| Tandem Diabetes Care, INC. | $61.16 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $55.73 | 2019-2020 | |
| Tolmar, INC. | $51.84 | 2024-2025 | Fensolvi |
| Abbott Laboratories | $50.66 | 2020-2025 | Freestyle Libre |
| Xeris Pharmaceuticals, INC. | $41.45 | 2020-2021 | |
| Medtronic, INC. | $40.13 | 2021-2025 | Minimed 780g |
| Amgen INC. | $30.30 | 2023 | Repatha |
| Biomarin Pharmaceutical INC. | $26.68 | 2019-2020 | |
| Tolmar Pharmaceuticals, INC. | $26.63 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $18.81 | 2025 | |
| Kyowa Kirin, INC. | $18.63 | 2024 | Crysvita |
| Sequel Med Tech, LLC | $18.57 | 2025 | Twiist |
| Eton Pharmaceuticals, INC. | $15.97 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.65 | 2019 | |
| Lilly USA, LLC | $14.50 | 2019 | |
| Lifescan, INC. | $13.97 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Cerame listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.